Cyclacel Pharmaceuticals, Inc. (CYCC)
Automate Your Wheel Strategy on CYCC
With Tiblio's Option Bot, you can configure your own wheel strategy including CYCC - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol CYCC
- Rev/Share -0.0039
- Book/Share 0.5718
- PB 2.9208
- Debt/Equity 0.0029
- CurrentRatio 5.6018
- ROIC -2.6759
- MktCap 37194741.0
- FreeCF/Share -1.4024
- PFCF -4.9525
- PE -1.4176
- Debt/Assets 0.0024
- DivYield 1.4371
- ROE -27.5203
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 1
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
CYCLACEL PHARMACEUTICALS ANNOUNCES STOCK SPLIT
Published: May 07, 2025 by: GlobeNewsWire
Sentiment: Neutral
BERKELEY HEIGHTS, NJ, May 07, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”), a biopharmaceutical company developing innovative medicines, today announced that it expects to implement a 1-for-16 reverse stock split on its shares of common stock effective May 12, 2025, with trading to begin on a split-adjusted basis at the market open on that day. Trading in the shares of common stock will continue on The Nasdaq Capital Market under the symbol “CYCC”. The new CUSIP number for the shares of common stock following the reverse stock split is 23254L884.
Read More
CYCLACEL PHARMACEUTICALS, INC. ANNOUNCES EXECUTION OF SHARE EXCHANGE AGREEMENT TO MAKE FITTERS SDN.
Published: May 06, 2025 by: GlobeNewsWire
Sentiment: Neutral
KUALA LUMPUR, MALAYSIA, May 06, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”) today announced that it entered into an Exchange Agreement with FITTERS Diversified Berhad (9318.KL; “FITTERS”), an investment holding company engaged, through its subsidiaries, in the business of the sale of fire safety materials, equipment and fire prevention systems, “Waste-To-Resource” services and real estate development and construction.
Read More
Cyclacel Pharmaceuticals Announces $1 Million Private Placement Offering of Convertible Preferred Stock
Published: March 24, 2025 by: GlobeNewsWire
Sentiment: Neutral
KUALA LUMPUR, Malaysia, March 24, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. ("Cyclacel") (NASDAQ: CYCC, NASDAQ: CYCCP), a biopharmaceutical company that develops innovative cancer medicine, today announced that it has entered into a securities purchase agreement for the sale of its convertible Series E Preferred Stock (“Preferred Stock”) in a private placement to certain accredited investors yielding gross proceeds of $1.0 million before deducting offering expenses. The offering closed on March 21, 2025.
Read More
Cyclacel Pharmaceuticals Announces Closing of a Change of Control Transaction and Appointment of New Executive Leadership
Published: February 27, 2025 by: GlobeNewsWire
Sentiment: Neutral
BERKELEY HEIGHTS, N.J., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. ("Cyclacel") (NASDAQ: CYCC, NASDAQ: CYCCP), a biopharmaceutical company that develops innovative cancer medicines, today announced a change in control and leadership on February 26, 2025.
Read More
About Cyclacel Pharmaceuticals, Inc. (CYCC)
- IPO Date 2004-03-16
- Website https://www.cyclacel.com
- Industry Biotechnology
- CEO Dr. Sing Ee Wong
- Employees 12